Tag: Repatha
The European Commission authorise use of evolocumab to reduce risk of myocardial infarction in patients with established cardiovascular disease
The European Commission (EC) has authorised a new indication in the evolocumab (Repatha, Amgen) ...
EBBINGHAUS trial shows non-inferiority of evolocumab for cognitive function in cardiovascular group
Amgen has announced detailed results from the evolocumab (Repatha) cognitive function trial (EBB...
ACC 2017: PCSK9 inhibitor evolocumab significantly reduces the risk of cardiovascular events
Data for a new drug that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) show tha...
Evolocumab significantly reduces risk of cardiovascular events
The FOURIER trial evaluating whether evolocumab (Repatha, Amgen) reduces the risk of cardiovascu...
AHA 2016: Two thirds of patients experience plaque regression with the PCSK9 inhibitor evolocumab
Amgen has announced that adding its PCSK9 inhibitor evolocumab (Repatha) to optimised statin the...
Positive top-line results from phase 3 GLAGOV imaging study of evolocumab
The Phase 3 GLAGOV (Global assessment of plaque regression with a PCSK9 antibody as measured by ...
